Compile Data Set for Download or QSAR
maximum 50k data
Found 47 Enz. Inhib. hit(s) with all data for entry = 3244
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395252((4aS,5aS or 4aR,5aR)-3-(Phenylamino)-2-(pyridin-4-...)
Affinity DataIC50:  4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395282(N-{4-[[(4aR,5aR) or (4aS,5aS)]-3-Anilino-5a-methyl...)
Affinity DataIC50:  4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395280(N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-Methyl-4-oxo-3-(p...)
Affinity DataIC50:  5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395255((4aR,5aR or 4aS,5aS)-5a-Methyl-3-(phenylamino)-2-(...)
Affinity DataIC50:  5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395275(N-4-[[(7R) or (7S)]-7-Methyl-4-oxo-3-(phenylamino)...)
Affinity DataIC50:  5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395253(US10308629, Example 15 | rel-(4aR,5aR)-N-4-[4-oxo-...)
Affinity DataIC50:  6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395256((4aS,5aS or 4aR,5aR)-5a-Methyl-3-(phenylamino)-2-(...)
Affinity DataIC50:  6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395260(3-(Phenylamino)-2-(pyridin-4-yl)-5,6,7,8-tetrahydr...)
Affinity DataIC50:  6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395254(US10308629, Example 16 | rel-(4aR,5aR)-5a-Methyl-3...)
Affinity DataIC50:  6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395263(N-{4-[(7RS)-3-Anilino-7-methyl-4-oxo-1,4,5,6,7,8-h...)
Affinity DataIC50:  7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395282(N-{4-[[(4aR,5aR) or (4aS,5aS)]-3-Anilino-5a-methyl...)
Affinity DataIC50:  7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395250(US10308629, Example 12 | rel-(4aR,5aR)-3-(Phenylam...)
Affinity DataIC50:  7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395257(N-4-[(4aR,5aR or 4aS,5aS)-5a-Methyl-4-oxo-3-(pheny...)
Affinity DataIC50:  8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395259(3-(Phenylamino)-2-(pyridin-4-yl)cyclohepta[b]pyrro...)
Affinity DataIC50:  8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395278(1-Methyl-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-methyl-4...)
Affinity DataIC50:  11nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395272((1S,2S)-2-Fluoro-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-...)
Affinity DataIC50:  11nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395285(N-{4-[[(4aS,5aS) or (4aR,5aR)]-3-anilino-5a-methyl...)
Affinity DataIC50:  12nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395284(N-{4-[[(4aR,5aR) or (4aS,5aS)]-3-anilino-5a-methyl...)
Affinity DataIC50:  13nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395272((1S,2S)-2-Fluoro-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-...)
Affinity DataIC50:  16nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395266(1-Fluoro-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-methyl-4...)
Affinity DataIC50:  17nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395280(N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-Methyl-4-oxo-3-(p...)
Affinity DataIC50:  18nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395249(US10308629, Example 11 | rel-(4aR,7aS)-6-Methyl-3-...)
Affinity DataIC50:  19nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395251((4aR,5aR or 4aS,5aS)-3-(Phenylamino)-2-(pyridin-4-...)
Affinity DataIC50:  19nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395276(2-Fluoro-2-methyl-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a...)
Affinity DataIC50:  22nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395278(1-Methyl-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-methyl-4...)
Affinity DataIC50:  22nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395262((7RS)-2-(2-Aminopyridin-4-yl)-7-methyl-3-(phenylam...)
Affinity DataIC50:  25nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395261(2-(2-Aminopyridin-4-yl)-7-methyl-3-(phenylamino)cy...)
Affinity DataIC50:  26nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395263(N-{4-[(7RS)-3-Anilino-7-methyl-4-oxo-1,4,5,6,7,8-h...)
Affinity DataIC50:  27nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395268(N-4-[rel-(4aS,5aR)-5a-Methyl-4,6-dioxo-3-(phenylam...)
Affinity DataIC50:  30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395270(1-Methyl-N-4-[rel-(4aS,5aR)-5a-methyl-4,6-dioxo-3-...)
Affinity DataIC50:  35nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395248(US10308629, Example 10 | rel-(5R,7S)-2-(3-Fluoropy...)
Affinity DataIC50:  35nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395258(N-4-[(4aS,5aS or 4aR,5aR)-5a-Methyl-4-oxo-3-(pheny...)
Affinity DataIC50:  36nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395267(1-Fluoro-N-4-[[(4aR,5aR) or (4aS,5aS)]-5a-methyl-4...)
Affinity DataIC50:  52nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395276(2-Fluoro-2-methyl-N-4-[[(4aS,5aS) or (4aR,5aR)]-5a...)
Affinity DataIC50:  53nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395244(N-4-[rel-(5R,7S)-6,6-Dimethyl-4-oxo-3-(phenylamino...)
Affinity DataIC50:  63nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395245(US10308629, Example 7 | methyl 4-[rel-(5R,7S)-6,6-...)
Affinity DataIC50:  68nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395271(4-Fluoro-3-methoxy-N-4-[rel-(4aS,5aR)-5a-methyl-4,...)
Affinity DataIC50:  71nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395269(N-{4-[rel-(4aR,5aS)-3-Anilino-5a-methyl-4,6-dioxo-...)
Affinity DataIC50:  110nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395243(N-4-[rel-(5R,7S)-6,6-Dimethyl-4-oxo-3-(phenylamino...)
Affinity DataIC50:  115nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395265(1-Fluoro-N-4-[rel-(4aS,5aR)-5a-methyl-4,6-dioxo-3-...)
Affinity DataIC50:  133nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395239(US10308629, Example 1 | rel-(5R,7S)-6,6-Dimethyl-3...)
Affinity DataIC50:  146nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395247(1-cyclopropyl-3-4-[rel-(5R,7S)-6,6-Dimethyl-4-oxo-...)
Affinity DataIC50:  240nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395246(1-4-[rel-(5R,7S)-6,6-Dimethyl-4-oxo-3-(phenylamino...)
Affinity DataIC50:  375nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395264(N-{4-[rel-(4aR,5aR)-3-Anilino-5a-methyl-4-oxo-1,4,...)
Affinity DataIC50:  630nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395241((5R,7S or 5S,7R)-2-(2-Aminopyridin-4-yl)-6,6-dimet...)
Affinity DataIC50:  648nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395240(US10308629, Example 2 | rel-(5R,7S)-2-(2-Aminopyri...)
Affinity DataIC50:  1.16E+3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM395241((5R,7S or 5S,7R)-2-(2-Aminopyridin-4-yl)-6,6-dimet...)
Affinity DataIC50:  2.93E+3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent